IMG_E1413

コメント

  • コメント (10)

  • トラックバックは利用できません。

  1. Development of the IV formulation expanded use to critically ill and unable-to-swallow patients.

  2. Diflucan may have in vitro synergy with flucytosine against some Candida species.

  3. Diflucan is a critical part of the antifungal arsenal in resource-limited settings.

  4. Diflucan can be considered for treatment of Malassezia folliculitis.

  5. May significantly increase cyclosporine and tacrolimus levels, requiring close monitoring.

  6. Its simplicity of use made it a cornerstone of early outpatient HIV management.

  7. Diflucan’s long half-life enables once-daily dosing, improving adherence.

  8. Therapeutic drug monitoring is not routinely required but can be useful in specific scenarios.

  9. Renal dose adjustment is mandatory for Diflucan due to its primary renal excretion.

  10. Diflucan is often used for prophylaxis in stem cell transplant recipients.